Commentaries

21st century pandemic, prehistoric clinical trials

The U.S. is trying to fight a 21st century pandemic with prehistoric clinical trials -- and achieving the kind of efficiency you might expect. In the last six months, tens of thousand of patients have...

China offers forward-thinking biotechs much more than an opportunity to get delayed clinical trials back on track

Weiji (危机), the Chinese term for crisis, combines the characters for “danger” and “opportunity,” an apt description of the challenge posed by COVID-19. While most of the world struggles with pandemic containment and ‘re-opening,’ China,...

Juneteenth and our path forward: Letter from BioCentury’s Co-Founders

Editor’s Note: BioCentury’s co-founders, Chairman Karen Bernstein, Ph.D., and President & CEO David Flores, have written to the company’s employees about BioCentury’s response to racism and racial inequities in healthcare. It is published in its...

Beyond molecules and microbes: biopharma's responsibility to racial justice in and outside its own walls

The killing of George Floyd has made it clear that life sciences leaders cannot focus exclusively on molecules or microbes, that their missions include helping to heal social as well as physical pathologies. The uncomfortable...

Industry is a white knight right now. Don’t throw it away

Biopharma is having a moment. All eyes are on drug, diagnostic and vaccine developers to get us out of this crisis and back to work. Now, companies -- individually and collectively -- must make good...

The missing dimension in COVID-19 vaccine development

While they race to create COVID-19 vaccines, governments, drug companies and the public health community must avoid a deadly mistake that has limited the effectiveness of other vaccines. From the moment a new medical product...

Can the economy be saved by your right to choose COVID testing?

Combined virus and antibody testing is our best opportunity to identify those who can immediately but carefully return to work, and in doing so restart the economy while minimizing the epidemic’s resurgence. We argue that...

Vaccine prospects for COVID-19: learnings from a 40-year biotech journey that’s still in progress

I have been in biotech research one way or another for over 40 years. This strange time of quarantine and self-isolation during the COVID-19 outbreak has given me time to reflect on how lessons from...

FDA’s hydroxychloroquine test

COVID-19 is testing FDA’s leadership. The agency’s performance will affect both the health of COVID-19 patients as well as public trust in the agency. One of many challenges facing FDA is whether to keep in...

Partnership offers hope for COVID drug development

As the world eyes a return to post-COVID crisis “normalcy,” a robust global recovery will depend on effective treatments and ultimately a vaccine. Yes, more than 400 research and clinical programs are already under way,...

Learning from AIDS: there’s more than one way to tame a virus

The HHS secretary promised a vaccine within two years. Anthony Fauci urged caution, telling reporters “we don’t have any idea how long it’s going to take to develop a vaccine, if indeed we will be...

How the U.K. healthcare sector is leveraging its strengths to beat COVID-19

Crisis is the mother of invention and COVID-19 is no exception. But amid all the gloom are signs of a nascent revolution in how we create and develop new drugs, vaccines and diagnostics. The U.K....

FDA is wrong on self-validation of COVID-19 tests

While the world waits for vaccines and therapies, smart use of public health measures is critical for beating COVID-19. Testing is the essential tool for guiding public health. FDA, America’s premier public health agency, contributed...

人人为我,我为人人: 协调全球监管,打赢新冠大流行这场硬仗

Publisher's note: the English language version of this article may be found here . 新冠疫情激起了全球医药产业的广泛响应, 许多公司正将其专精与技术投入其中, 开发疫苗和疗法。 然而, 在不同国家或地区的监管上, 我们还没有看到全球总协同。 相反, 许多监管上的决策只局限于不同的国家层面, 让全产业的努力显得支离破碎...

Biopharma must step up for those on the front lines of COVID-19

While not every biotech can develop countermeasures for COVID-19, nearly all can contribute by providing urgently needed resources to protect the clinicians and other essential workers holding the line against catastrophe, and by making their...